Genesis Biopharma (GNBP) Expands Focus to Develop Melanoma Treatment
Genesis Biopharma Inc., a biotech company developing targeted cancer therapies, is expanding its clinical focus to include an autologous cell therapy product candidate Contego™ as treatment of stage IV metastatic melanoma. The company noted that the product name “Contego” is well fitting of the treatment’s designated application - a Latin term meaning to shield or to protect. Genesis Biopharma will develop Contego as a ready-to-infuse autologous cell therapy product that contains tumor infiltrating lymphocytes (TILs) taken from a patient's metastatic melanoma tumors. Genesis Biopharma explained that after resection of the patient's tumor, TILs are isolated from the resected tumor and…